Metachronous neoplasms have rarely been reported in patients with neuroblastoma. This report presents the clinical case of a 23-monthold child who was diagnosed with an anaplastic medulloblastoma 5 months after completing treatment for stage IV neuroblastoma. The patient was treated with complete surgical resection and adjuvant chemoradiation followed by maintenance chemotherapy at an outside institution and came to our institution for further management. A pathologic diagnosis and review of both the suprarenal and posterior fossa masses were performed, as well as a genetic analysis of both cerebellar tumor tissue and blood using next-generation gene sequencing. At our institution, the patient was submitted to induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation and remains free of disease 2 years after completion of treatment. Genetic analysis revealed multiple somatic copy number variations with most deleted genes located in 2q37, a region which harbors genes involved in epigenetic regulation and tumor suppression. A homozygous deletion was found in the TSC2 gene, which is a clinically actionable gene, and patients with activating deletions in TSC2 can potentially be eligible for basket clinical trials with mTOR inhibitors. Germline single nucleotide variants were also identified in multiple genes involved in cancer (ALK, FGFR3, FLT3/4, HNF1A, NCOR1, and NOTCH2/3), cancer predisposition (TP53, TSC1, and BRCA1/2), and genes involved in DNA repair (MSH6, PMS2, POLE, and ATM). Metachronous neoplasms are rare and challenging to treat, hence genetic analysis and referral are needed to exclude hereditary cause. DNA sequencing of the tumor and germline can help identify alterations that increase predisposition or can be used to guide treatment decisions on recurrence and when standard options fail.
Embryonal neoplasms of the central nervous system (CNS) represent nearly one-third of brain tumors in children aged <3 years. 1, 2 Medulloblastoma with its different histologic variants belongs to this group, representing up to 20% of pediatric CNS tumors. Cerebellar neuroblastoma is an extremely uncommon entity of this group with few published reports on primary cerebellar neuroblastoma. 3, 4 A number of second neoplasms have been reported in patients with neuroblastoma, including CNS tumors (gliomas and meningioma), but no prior reports of medulloblastoma. These second primary can- cers have mostly occurred many years after long-term surveillance. [5] [6] [7] This report presents a case of medulloblastoma in a child 5 months after successful treatment of stage IV neuroblastoma, and discusses the findings in the DNA sequencing results of both the resected posterior fossa tumor and the germline mutations.
Methods

Approval was obtained from The University of Texas MD Anderson Cancer Center Institutional Review
Board for this study (Clearing House protocol by Dr. Funda Meric-Bernstam), and informed consent was obtained. Separate consent for the molecular studies and analysis was also obtained. Pathologic diagnosis and review of the suprarenal and posterior fossa masses was performed by members of the Division of Pathology and Laboratory Medicine. Immunohistochemical studies that are pertinent to neuroblastoma and medulloblastoma tumors were used, including CD57 and neurofilaments.
DNA Sequencing and Analysis
Genomic DNA was quantified by PicoGreen (Invitrogen, Ltd.) and quality was assessed using Genomic DNA ScreenTape for the 2200 TapeStation (Agilent Technologies). Library preparation, targeted capture, and data analysis were completed as previously described. 8 For data analysis, the T200 targetcapture deep-sequencing data was aligned to human reference assembly hg19 using the Burrows-Wheeler Alignment tool 9 and duplicated reads were removed using Picard. 10 Single nucleotide variants and small insertions/deletions were detected using an inhouse-developed analysis pipeline, 11 which classified variants into 3 categories: somatic, germline, and loss of heterozygosity based on variant allele frequencies in the tumor and the matched normal tissues. Copy number alterations were determined using a previously published algorithm, 12 which reports gain or loss status of each exon. To understand the potential functional consequence of detected variants, we compared them with the SNP Database, Catalogue of Somatic Mutations in Cancer, 13 and The Cancer Genome Atlas database, and annotated them using VEP, 14 ANNOVAR, 15 CanDrA, 16 and other programs. Translation consequence of the alteration, such as nonsynonymous, missense, stop-gain, frameshift, and others, follows Sequence Ontology (http:// www.sequenceontology.org). All aberrations that are nonsynonymous were shown. The software used for predicting consequences and clinical implications has been previously described: PolyPhen (the higher the score, the more damaging the aberration), 17 SIFT (the lower the score, the more deleterious the aberration), 18 and CanDrA 16 to identify whether the mutation is the driver versus the passenger.
Case Description
A 10-month-old girl presented with 2-month history of proptosis and progressive periorbital ecchymosis. She was born full-term via vaginal delivery and has an insignificant past medical history, and her family history was negative for cancer. A CT scan revealed a right retro-orbital mass measuring 2.7 x 1.2 x 1.8 cm. A CT of the abdomen showed a calcified right adrenal mass measuring 6.5 x 5.5 x 5.5 cm with liver metastasis. Evaluation studies for staging including metaiodobenzylguanidine (MIBG) revealed disease at the anterior mediastinum, liver, bone marrow, skull, and third lumber vertebra. Brain MRI revealed disease in the right orbital fossa extending to the middle cranial fossa, with no intracranial or cerebellar disease. The patient underwent fine-needle aspiration biopsy of the orbital mass, and neuroblastoma was diagnosed. A urine catecholamine test was performed initially and reported to be unremarkable; however, upon patient transfer to a tertiary facility with a pediatric oncology floor, this test was repeated and found to be elevated (91 ng/mL vs a normal institutional laboratory reference range of 15.7-17.0 ng/mL). Further staging evaluation was performed, including spine MRI and spinal tap, and found to be negative for disease.
Chemotherapy with vincristine, cyclophosphamide, cisplatin, and doxorubicin was initiated. After the first 2 cycles of chemotherapy, the patient underwent disease evaluation. Laparotomy and resection of the right adrenal mass and adjacent lymph nodes were performed, and pathology confirmed the diagnosis of neuroblastoma with poor differentiation and extensive treatment-related changes (necrosis and calcification) ( Figure 1A ). No NMYC amplification or 1p or 17q deletion were seen, and her karyotype was unremarkable. The patient was classified as having intermediate-risk disease and resumed chemotherapy consisting of vincristine, cyclophosphamide, cisplatin, dacarbazine, ifosfamide, and doxorubicin, followed by 5 maintenance cycles of 13-cis retinoic acid. Surveillance MIBG during maintenance chemotherapy revealed no residual disease.
Five months after completing treatment, the patient presented with repeated vomiting and new onset of difficulty walking after experiencing head trauma. MRI of the brain showed a mass in the right cerebellar hemisphere with hydrocephalus ( Figure 1E ). Com-plete surgical resection of the mass was performed and pathology revealed anaplastic medulloblastoma (Figure 1B) . Metastatic workup, including spine MRI, spinal tap, urine catecholamine testing, and MIBG scan, was negative for disease ( Figure 1F -H).
Chemoradiation with vincristine was initiated, and a brain MRI following completion was negative for disease. The treatment was stopped because disseminated fungal infection was suspected after the patient developed fever and neutropenia, and CT of the liver showed some nodularity but blood culture results were negative. Antifungal therapy was initiated for a total of 6 weeks. The treating team decided to decrease treatment intensity and the patient was switched to metronomic therapy with oral cyclophosphamide and topotecan for 2 cycles. The patient came to The University of Texas MD Anderson Cancer Center (MDACC) for a second opinion and further management. A review of the pathology at MDACC agreed with the findings of a small round blue cell tumor, positive CD57 test results, and the absence of neuroblastic differentiation, which indicate the diagnosis of medulloblastoma, anaplastic variant ( Figure 1C, D) . Considering the prior treatment of neuroblastoma and the incomplete treatment of medulloblastoma, the team decided to proceed with second-line chemotherapy with temozolomide and irinotecan for relapsed medulloblastoma and, if the patient responded well, to follow with high-dose chemotherapy and autologous stem cell transplant (SCT) for curative intent. She was started on temozolomide (150 mg/m 2 x 5 days) and irinotecan (50 mg/m 2 x 5 days) every 28 days for 5 cycles.
No disease recurrence was seen on end-of-induction imaging and spinal tap, and therefore the patient proceeded with a planned 3 tandem autologous SCT with a conditioning regimen of carboplatin and thiotepa. The patient tolerated the treatment well, and end-of-treatment brain and spine MRI and lumbar puncture revealed no evidence of disease. At time of writing, the patient continues to be in remission from both diseases for >2 years posttreatment.
DNA Sequencing and Copy Number Analysis
A genetic analysis of the medulloblastoma sample was performed using a targeted panel of 263 cancerrelated genes. 8 Supplemental eTable 1 (available with this article at JNCCN.org) illustrates the genes However, copy number analysis of the cerebellar tumor tissue identified homozygous deletions (H. DEL ≤1 copy) of various genes, including AT-G4B, AXIN1, CREBBP, D2HGDH, FBRS, GPC1, GPR35, HDLBP, ING5, KIF1A, PASK, PPP1R7, SNED1, and TSC2, as well as high amplification (H. AMP ≥4 copies) of the TOP1 and SOX4 genes (Table 1, Figure 2A ). Interestingly, most of the deleted genes were located in chromosome 2 (q37.3) and, less commonly, chromosome 16 (p11-13). Many other focal areas of lower level deletion or amplification were also observed in the cerebellar tumor, suggesting a moderate level of genomic instability ( Figure 2B ).
Germline DNA from blood was also tested using the same gene panel. Among hundreds of single nucleotide polymorphisms (SNPs) detected, we selected nonsynonymous alterations that are related to cancer (ALK, FGFR3, FLT3/4, HNF1A, NCOR1, and NOTCH2/3), cancer predisposition (TP53, TSC1, and BRCA1/2), and DNA repair (MSH6, PMS2, POLE, and ATM) ( Table 2) . On further analysis of the germline data using state of the art literature-based methodology to identify possible damaging, deleterious, and potentially driver mutations, [15] [16] [17] [18] we refined the list of germline SNPs of interest to include FGFR3, FLT3/4, HNF1A, NCOR1, and NOTCH3. Unfortunately, not enough viable tissue was available to perform sequencing of the adrenal tumor.
Discussion
The occurrence of metachronous neoplasms is rare in children, with only a few reported cases in patients with neuroblastoma, including renal cell carcinoma, epithelioid tumor, and astrocytoma, but not medulloblastoma. [19] [20] [21] Furthermore, cancer survivors are at a higher risk of second cancers compared with the general population. Analyses of 9,432 long-term neuroblastoma survivors in 3 major studies indicated that 96 patients developed second cancers, including carcinomas, soft tissue sarcomas, glioblastomas, meningioma, melanomas, and hematologic malignancies, but none developed medulloblastoma (Table 3) . [5] [6] [7] Neuroblastoma and, less commonly, medulloblastoma, have been reported in patients with cancer predisposition syn- Figure 2A) . Some of the deleted areas are in genes involved in the epigenetic regulation (D2HG-DH, ING5, PASK, PPP1R7, KIF1A, and CREBBP), whereas others act as putative tumor suppressor genes (TSC2, AXIN, KIF1A, and ATG4B). Importantly, deletions of TSC2 are potentially actionable, and on clinical validation, patients harboring these aberrations can be eligible for targeted therapy using mTOR inhibitors. 25 Therefore, this particular somatic deletion could guide treatment decisions for this patient after recurrence.
Recent studies have shown chromosome 2 microdeletions in several cancers, such as neuroblastoma and breast, lung, and cervical cancers. [26] [27] [28] [29] Strikingly, most of the deletions detected in this patient sample are in genes located in Chr2 q37.3 (Table 1, Figure 2A) , an area that harbors many genes involved in skeletal and neuronal development. Although the 2q37.3 deletion was a somatic event for our patient, it is interesting to mention that the 2q37 deletion syndrome consists of a germline loss of Chr2 (q37.1, q37.2, q37.3). 30 Children with this syndrome present with developmental delays and learning disabilities, as well as autism-like symptoms, seizures, and low muscle tone, among other symptoms. However, no germline 2q37 deletion was observed in our patient.
Another intriguing finding was the presence of multiple nonsynonymous germline alterations in genes involved in DNA repair (BRCA 1/2, MSH6, PMS2, POLE, ATM, and ATR) and cancer-predisposing syndromes (TP53 and TSC1). On further analysis, few alterations were found to be clinically relevant; for example, we found POLE to be deleterious, BRCA1 to be damaging, and MSH6 to be both damaging and deleterious. Surprisingly, a group of genes that were found to be damaging, deleterious, and possible drivers includes NOTCH3, FGFR3, FLT3, FLT4, HNF1A, and NCOR1, which have been recognized in literature to play a role in cancer tumorigenesis. Several past studies suggest that genetic alterations in DNA damage response genes can determine the individual risk of developing cancer. 29, 31 MSH6 and PMS2 genes belong to the mismatch repair system and play a basic role in genome integrity maintenance by correcting single base pair mismatches after DNA replication. Mutations of the aforementioned genes have been reported in cancer predisposition syndromes, including Turcot and 
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Lynch syndromes, and are associated with colorectal, brain, and other cancers. 32, 33 Furthermore, other genes belonging to the DNA repair machinery, including ATM and POLE, constitute a network that is crucial for genomic stability, acting as a barrier against tumorigenesis.
Other germline alterations were detected in genes that also seem to play a role in tumorigenesis and tumor progression, but mostly in a somatic context. [34] [35] [36] [37] [38] For example, somatic aberrations in fibroblast growth factor receptor 3 (FGFR3), which is a tyrosine kinase receptor for the FGF ligands, confer a selectable survival advantage in multiple solid tumors. 39 The FGFR3IIIS is a splice variant that may act as a dominant negative, inhibiting FGFR3- All aberrations shown are non-synonymous. The software used for predicting consequences and clinical implications have been previously described: (1) PolyPhen (the higher the score, the more damaging is the aberration), (2) SIFT (the lower the score the more deleterious the aberration), and (3) and CanDrA. Abbreviations: AA, amino acid; dbSNP, database single nucleotide polymorphism.
induced growth arrest and differentiation, and has been detected in both medulloblastoma and neuroblastoma. 40 Another example, the FLT3 gene, which encodes a receptor tyrosine kinase, is a cytokine receptor that regulates hematopoiesis and mutations in this receptor, and can result in acute myeloid leukemia and acute lymphoblastic leukemia. 41 Treatment with FLT3 ligand induces proliferation and growth in neuroblastoma cell lines, which was significantly inhibited with FLT3 antisense, indicating a role in tumorigenesis. FLT4 is a receptor tyrosine kinase for VEGF-C and VEGF-D ligands, and plays vital role in angiogenesis through activation of AKT and MAPK signaling pathways, which promote proliferation, survival, and migration of endothelial cells, and reg- ulates angiogenic sprouting. FLT4 has been found to be overexpressed in tumors, including medulloblastoma, glioblastoma, and neuroblastoma, and confers poor outcome in neuroblastoma. 42, 43 Finally, Notch receptors play an essential role in the regulation of central cellular processes during embryonic and postnatal development, and has been implicated in several cancers, including leukemia, glioma and medulloblastoma. 44 The Notch pathway prevents neuronal differentiation in the CNS by driving neural stem cell maintenance, and is therefore often implicated in the growth, survival, invasion, and recurrence of brain tumors. Moreover, neuroblastoma has high expression of Notch3, and its downstream-regulated genes have mesenchymal characteristics and are associated with an increased incidence of metastases and poor prognosis. 45 When this patient presented to MDACC, we were faced with 2 challenges: (1) determining whether the cancer was medulloblastoma versus neuroblastoma, and (2) dealing with the nonstandard treatment approach that was used at the abroad institution. Neuroaxial metastasis of neuroblastoma is not uncommon, and usually occurs at a median of 18 months in high-risk groups with elevated catecholamine. Furthermore, metastatic CNS neuroblastoma frequently appears as a leptomeningeal or interventricular mass, and less commonly as a parenchymal mass (with the frontal lobe the most common location), and not in the cerebellum. In our patient's case, results of the catecholamine test were negative and the tumor was in the cerebellum, and the lack of neurofilament staining and absence of neuroblastic differentiation favored the diagnosis of medulloblastoma. An entity called cerebellar neuroblastoma has been reported rarely in the literature, but there has been no report of its coexistence with extracranial neuroblastoma.
In infant medulloblastoma, high-dose chemotherapy and autologous SCT is a preferred treatment strategy to delay radiation and avoid its deleterious late effect. 46 Despite complete tumor resection and postoperative radiation therapy in our patient, and because the medulloblastoma was high-risk (due to its anaplastic histologic type and the patient's young age), we proceeded with induction chemotherapy followed by high-dose chemotherapy and autologous SCT to augment the suboptimal dose of radiation and incomplete treatment that was administered at the previous institution.
Regarding management and the therapeutic impact of molecular testing, the patient and parents were referred to genetic services and the parents were offered genetic testing but decided not to proceed. Our recommendation for follow-up was to perform annual whole-body surveillance imaging with dedicated brain MRI and blood counts. Regarding treatment, future target agents to be considered in the event of recurrence include PARP inhibitors, with literature supporting their use in tumors with DNA damage repair genes alterations (POLE, MSH6, BRCA1/2). 47 Recently, PD-L1 inhibitors were postulated to be efficacious in treating patients with cancer with mismatch gene repair mutations (MSH6) and/or hypermutation. 48 This is in addition to other potential targets, such as mTOR inhibition (for tumors with TSC2 deletion).
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Conclusions
Metachronous neoplasms are rare and challenging to treat; hence, genetic testing and referral are needed to exclude familial cancer syndromes and to aid in treatment planning. In addition, DNA sequencing of the tumor can help to identify actionable somatic alterations that could guide treatment decisions when standard treatment fail upon recurrence.
